At CD ComputaBio, we recognize that the development of orally bioavailable cyclic peptides represents one of the most promising yet technically challenging frontiers in modern drug discovery. Our AI-driven platform bridges the gap between computational innovation and therapeutic reality, offering an end-to-end solution that integrates generative design, multi-parameter optimization, and experimental validation. By combining proprietary machine learning algorithms with deep domain expertise in macrocycle chemistry, we empower pharmaceutical and biotech partners to tackle previously undruggable targets with speed, precision, and confidence.
Figure 1. Process of AI-Driven Oral Cyclic Peptide Drug Design Service.
Cyclic peptides occupy a unique space between small molecules and biologics, yet achieving oral bioavailability remains a formidable challenge. At CD ComputaBio, we have built the industry's most advanced AI-powered platform dedicated to rational design of orally active cyclic peptides. Our system integrates physics-based molecular dynamics, machine learning permeability models, and synthetic feasibility filters within a unified digital environment. This "AI + medicinal chemistry" powerhouse eliminates traditional trial-and-error cycles. While our algorithms explore vast chemical space and predict key ADMET properties, our expert scientists focus on strategic optimization and experimental validation — ensuring that candidates possess both high affinity and favorable pharmacokinetics.
Figure 2. Application Scenarios of AI-Driven Oral Cyclic Peptide Drug Design Service.
Oral Macrocycle Discovery: Design cyclic peptides with optimized passive permeability and metabolic stability for oral administration.
Target Class Expansion: Address challenging targets (PPIs, ion channels, GPCRs) by leveraging conformational constraint and macrocyclic topology.
Lead Optimization & ADMET Tuning: AI-guided side-chain modifications to enhance bioavailability while retaining potency and selectivity.
Natural Product Mimetics: Transform natural cyclic peptides into drug-like, orally available scaffolds using de novo design.
Generative Cyclic Peptide Design
Deep generative models trained on macrocycle databases to propose novel, synthesizable sequences with predicted oral absorption. Our approach significantly expands the accessible chemical space beyond traditional peptide libraries, uncovering diverse scaffolds with favorable drug-like properties.
Oral Cyclic Peptide ADMET Prediction Service
Machine learning classifiers and MD-based membrane simulation to rank-order candidates by passive permeability and efflux risk. This predictive layer allows early elimination of compounds with poor absorption potential, drastically reducing downstream experimental attrition.
Oral Cyclic Peptide Drug Optimization Service
AI-powered iterative refinement of lead candidates to enhance potency, selectivity, and metabolic stability. Our optimization engine systematically explores substitution patterns, macrocyclization strategies, and physicochemical tuning to rapidly advance initial hits toward development-ready candidates with balanced ADMET profiles.
Conformational Analysis & SAR
High-throughput conformational sampling to link 3D structure with bioactivity and metabolic hotspots. By understanding the dynamic behavior of cyclic peptides, we enable rational optimization that preserves the bioactive conformation while enhancing stability and permeability.
AI-Powered Library Design/customized
Virtual screening of proprietary and public cyclic peptide libraries against therapeutic targets. Our screening engine can rapidly identify starting points from millions of macrocycle structures, providing a rich foundation for subsequent optimization.
Collaborative experimental packages including Caco-2 permeability, plasma stability, and metabolic assays. We close the loop between computation and experiment, enabling iterative refinement that continuously improves prediction accuracy and candidate quality.
Our AI-driven oral cyclic peptide drug design process is designed for efficiency, accuracy, and compliance at every stage:
AI models propose cyclic peptide cores with optimized ring size, N-methylation patterns, and side-chain chemistries to favor oral absorption. This initial phase leverages deep generative networks trained on high-quality macrocycle datasets to ensure chemical diversity and synthetic tractability.
Proprietary algorithms predict logP, PSA, and transcellular permeability using graph neural networks and ensemble classifiers. Our models account for the chameleonic behavior unique to cyclic peptides, providing accurate predictions that align closely with experimental permeability measurements.
Molecular dynamics simulations assess bioactive conformation stability and identify proteolytic cleavage sites. This step ensures that designed molecules maintain their functional shape in physiological environments while minimizing susceptibility to metabolic degradation.
AI-driven ranking delivers top candidates with synthetic routes, ADMET summary, and interactive 3D models for decision making. Each final report is tailored to support go/no-go decisions with clear rationale.
Unmatched Speed & Efficiency
Reduce design cycles from months to weeks. Our platform evaluates millions of virtual cyclic peptides in days, focusing synthesis only on high-value candidates. This accelerated workflow allows multiple design iterations within a typical project timeline, increasing the probability of identifying a viable clinical candidate.
Integrated Physics + AI
Unique combination of quantum mechanics, MD simulations, and deep learning — enabling accurate permeability prediction beyond simple rule-of-five. By integrating first-principles physics with data-driven models, we capture the complex molecular interactions that govern cyclic peptide behavior in ways that pure statistical approaches cannot.
Proven Expertise
Team of medicinal chemists and computational biologists with decades of experience in macrocycle drug discovery and oral peptide development. Our scientists bring hands-on knowledge of what makes a cyclic peptide not just potent on paper, but truly developable as a therapeutic candidate.
Connect with Us Anytime!
The future of oral cyclic peptide therapeutics is intelligent, automated, and integrated. By combining AI-driven design with world-class drug discovery expertise, we transform challenging targets into clinical candidates. Experience a modern, software-based approach to macrocycle drug discovery.
